Trade Margin Rationalisation on 137 Anti-Cancer Drugs
Ministry of Chemicals and Fertilizers - Department of Pharmaceuticals · Health · Posted 17 OCT 2026 6:53PM
What happened
The National Pharmaceutical Pricing Authority (NPPA) under the Ministry of Chemicals and Fertilizers has capped trade margins at 30% for 137 non-scheduled anti-cancer drugs, reducing their MRP by up to 70% effective November 9, 2026.
Why it matters for UPSC
This update illustrates government intervention in healthcare pricing and regulation, directly relevant to the UPSC syllabus regarding issues relating to development and management of social sectors/services relating to Health.
Key objectives
- National Pharmaceutical Pricing Authority (NPPA) has undertaken Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, capping trade margins at 30% of the Maximum Retail Price (MRP).
- The revised prices will become effective from November 9, 2026, and are expected to reduce MRP by up to 70%.
- The measure is carried out under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, based on recommendations from an Expert Committee under the DGHS.